arrow
P

Patricia Winokur

University of Iowa
H指数:39
被引数:5,954

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone® or Flublok®) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18-45 years of age

一项关于两种四价季节性流感疫苗(Fluzone®或Flublok®)在18-45岁健康成年人中,单独使用或与两种佐剂(AF03或Advax-CpG55.2)联合使用时的安全性、反应原性和免疫原性的I期研究

VACCINE
IF3.5
2025-04-010
PRE
Population Pharmacokinetic Modeling of Cefepime, Meropenem, and Piperacillin-Tazobactam in Patients With Cystic Fibrosis

囊性纤维化患者中头孢吡肟,美罗培南和哌拉西林-他唑巴坦的群体药代动力学模型

2024-09-300
PRE
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial
2024-09-261
PRE
A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults

一项2期临床试验,用于评估在健康美国成年人中使用和不使用AS03佐剂的2013年和2017 A(H7N9) 灭活流感病毒疫苗的安全性,反应原性和免疫原性

2024-03-274
PRE
Daily fosfomycin versus levofloxacin for complicated urinary tract infections

每日磷霉素与左氧氟沙星治疗复杂的尿路感染

MBIO
IF4.7
2023-10-314
OAAI
Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial
2023-08-2819
OAAI
Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial
2023-08-101
OA
Safety and Immunogenicity of a Delayed Heterologous Avian Influenza A(H7N9) Vaccine Boost Following Different Priming Regimens: A Randomized Clinical Trial

不同启动方案后延迟异源禽流感a (H7N9) 疫苗加强的安全性和免疫原性: 一项随机临床试验

2023-07-193
OA
Population pharmacokinetics and target attainment analyses to identify a rational empirical dosing strategy for cefepime in critically ill patients

群体药代动力学和目标达成分析,以确定重症患者头孢吡肟的合理经验给药策略

2023-04-183
OA
Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial
2023-04-1011
OA
Evaluation of Empirical Dosing Regimens for Meropenem in Intensive Care Unit Patients Using Population Pharmacokinetic Modeling and Target Attainment Analysis

基于群体药代动力学模型与目标达标分析对重症监护病房患者美罗培南经验性给药方案的评价

2023-01-248
OA
Bivalent Omicron BA.1-Adapted BNT162b2 Booster in Adults Older than 55 Years

55岁以上成人的二价Omicron BA.1适应BNT162b2助推器

2023-01-1973
OAAI
Pharmacokinetics, Safety, and Tolerability of Oxfendazole in Healthy Volunteers: a Randomized, Placebo-Controlled First-in-Human Single-Dose Escalation Study
2019-04-0129
OAAI

研究方向

暂未获取到该数据
暂无数据